Cancer Immunotherapy Market
According to research report the Cancer Immunotherapy Market is projected to reach USD 119.39 Billion by 2021 from USD 61.97 Billion in 2016, at a CAGR of 14.0%.
In this report, the global cancer immunotherapy market has been segmented based on type, application, end user, and region.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197577894
Market
growth factors such as increasing adoption of target therapy over
traditional therapy, emergence of biosimilars, increasing demand for
mAbs, high prevalence of cancer. Cancer immunotherapy drugs are designed
to alter or boost the body’s natural immune response to fight cancer
this market is research-driven with a high degree of dependence on the
discovery of molecules that can generate an immune response against
various indications.
On the basis of applications, the global
cancer immunotherapy market is segmented into lung cancer, breast
cancer, colorectal cancer, melanoma, prostate cancer, head & neck
cancer, and others. The lung cancer segment is expected to grow at the
highest CAGR during the forecast period. The high growth in this segment
can be attributed to the increasing prevalence of this type of cancer
and rising demand for advanced treatment options.
On the basis of
type, the market has been segmented into monoclonal antibodies, cancer
vaccines, checkpoint inhibitors, and immunomodulators. The monoclonal
antibodies segment is expected to account for the largest share of the
market in 2016, while the checkpoint inhibitors segment is projected to
witness the highest CAGR from 2016 to 2021. The high growth in this
segment is primarily attributed to the high success rate of these
inhibitors.
Based on regions, the global Cancer Immunotherapy
market is segmented into North America, APAC, Europe and the Rest of the
World (RoW). North America is expected to account for the largest share
of the market during the forecast period. Growth in this regional
segment is driven by factors such as increase in patient pool, and
initiative taken by the government for the development of Cancer
Immunotherapy.
Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=197577894
Key
players in the cancer immunotherapy market include Amgen (U.S.),
AstraZeneca (U.K.), F. Hoffmann-La Roche AG (Switzerland), Bayer AG
(Germany), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.),
Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis
(Switzerland), and Pfizer (U.S.).
